DirectMeds vs MedVi 2026: GLP-1 Price & Support

DirectMeds vs MedVi 2026: GLP-1 Price & Support. Direct Meds vs MedVi compared. Pricing, GLP-1 medications, clinical support, and which telehealth provider is right for you. If you're considering GLP-1 weight loss medication through telehealth, DirectMeds and MedVi are two names that keep coming up. Both platforms let you consult with a licensed provider online, get prescribed compounded semaglutide or tirzepatide, and have it shipped to your door — no in-person visits required. But despite the similar pitch, these are different companies with different strengths. This head-to-head comparison breaks down everything you need to know: pricing, medications, clinical support, delivery, and overall value. By the end, you'll know exactly which platform fits your situation. DirectMeds Overview DirectMeds has built its brand around two promises: transparent pricing and fast delivery. The platform offers both compounded semaglutide and tirzepatide through a fully digital process — complete your intake, get evaluated by a licensed provider, and have your medication shipped directly to your door. The streamlined approach eliminates the back-and-forth that plagues some telehealth platforms, getting patients from sign-up to first shipment as quickly as possible. DirectMeds also provides nurse support alongside prescriptions, which adds a clinical touchpoint that pure prescription-by-mail services lack. The platform maintains an active social media presence across Facebook, Instagram, and YouTube, regularly publishing educational content about GLP-1 medications and weight loss. For patients who value a straightforward, no-nonsense experience, DirectMeds delivers exactly that. MedVi Overview MedVi is one of the largest GLP-1 telehealth platforms in the U.S., having served over 500,000 patients and generated $1.6 billion in first-year sales. That kind of scale translates directly into operational reliability: established pharmacy relationships, consistent medication supply, battle-tested support infrastructure, and the institutional knowledge that comes from handling hundreds of thousands of patient interactions. The platform offers compounded GLP-1 medications with 24/7 unlimited clinical support, a dedicated patient portal for progress tracking, and LegitScript verification. MedVi emphasizes clinician-directed care — your prescribing provider actively manages your protocol, adjusting dosing based on your response, side effects, and progress rather than following a rigid one-size-fits-all schedule. Medications Compared Both DirectMeds and MedVi offer the two most commonly prescribed compounded GLP-1 medications: semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (the active ingredient in Mounjaro and Zepbound). This means your core treatment options are identical regardless of which platform you choose. The key difference is in how each platform structures access to these medications. DirectMeds lets you get prescribed either compound through its streamlined online intake — the emphasis is on getting you matched with the right medication quickly. MedVi takes a more consultative approach, with clinician-directed protocol selection based on your health profile, goals, and medical history. Both methods are medically valid; the question is whether you prefer speed or a more guided clinical process. Pricing and Value DirectMeds positions itself on transparent pricing — what you see is what you pay, with medication, provider consultation, and shipping bundled into the monthly cost. The platform has made pricing clarity a core part of its brand, which resonates with patients tired of surprise fees from other telehealth providers. Both semaglutide and tirzepatide are available, with tirzepatide typically priced higher due to higher manufacturing costs. MedVi operates in a similar price range, with standard monthly rates that include medication, consultations, and shipping. MedVi also emphasizes "clear pricing with no hidden fees" — no surprise lab costs or consultation charges beyond what's quoted upfront. Clinical Support This is where the platforms diverge most significantly. MedVi offers 24/7 unlimited clinical support through its patient portal — you can reach a medical professional any time, day or night. That around-the-clock availability is a meaningful differentiator, especially during dose titration when side effects are most common and questions come up at unpredictable hours. DirectMeds includes nurse support as part of its service — patients have access to nursing staff who can answer questions about their medication, side effects, and treatment protocol. While not 24/7, this clinical touchpoint goes beyond what some platforms offer. DirectMeds' approach fits patients who want clinical access available when they need it without the full concierge-level support model. Getting Started: The Intake Process DirectMeds has optimized for speed. The platform's digital-first approach means you can complete the intake, get evaluated, and have your prescription issued in a streamlined workflow. The goal is to minimize the time between deciding to try GLP-1 medication and receiving your first shipment. For patients who've already done their research and know they want to start treatment, this efficiency is a major selling point. MedVi uses a four-step process: intake questionnaire, provider review, clinical consultation (1:1 with a physician), and medication delivery. The consultation step adds time but also adds a layer of clinical thoroughness — your provider reviews your health history, discusses medication options, and develops a personalized protocol before anything is prescribed. Delivery and Pharmacy Both platforms ship compounded GLP-1 medications directly to patients from licensed U.S. compounding pharmacies. DirectMeds emphasizes fast delivery as a core feature — the platform understands that once a patient is approved, any delay in receiving medication creates friction. Medications arrive at your door with everything needed for self-administration. MedVi also offers fast, discreet shipping from FDA-regulated compounding facilities. The platform holds LegitScript certification, which is a third-party verification that adds credibility to its pharmacy sourcing. Both providers work with 503B outsourcing facilities that operate under FDA oversight, meaning the medication quality standards are comparable between platforms. Track Record and Trust MedVi has the clear advantage in track record. With 500,000+ patients served and $1.6 billion in first-year revenue, MedVi has operated at a scale that stress-tests every aspect of a telehealth business. That operational maturity doesn't guarantee a perfect experience for every patient, but it dramatically reduces the likelihood of supply disruptions, support gaps, or operational issues. DirectMeds is building its reputation through consistent service and patient satisfaction. The platform regularly updates its offerings and maintains active community engagement through social media. While it hasn't reached MedVi's scale, DirectMeds' focused approach — do one thing well (GLP-1 prescriptions with fast delivery) — has earned it a growing base of loyal patients who value simplicity over breadth. Which Should You Choose? Both DirectMeds and MedVi are legitimate platforms offering real GLP-1 medications with clinical oversight. The right choice depends on what you prioritize: Choose DirectMeds if you want a fast, streamlined experience with transparent pricing, nurse support, and both semaglutide and tirzepatide available. DirectMeds is ideal for patients who've done their research, know what they want, and value efficiency over hand-holding. Choose MedVi if you want the security of a proven, large-scale platform with 24/7 clinical support and a structured clinical relationship. MedVi's operational maturity, LegitScript verification, and massive patient base provide unmatched peace of mind. PeptideStack page context: visitors can use the header navigation to reach the product catalog, blog, calculators, supplier pages, discount-code pages, contact page, legal policies, shipping policy, refund policy, privacy policy, terms, and research disclaimer. The site is organized around research peptide education, supplier transparency, product comparison, vendor review content, discount-code tracking, and calculator tools for reconstitution or unit conversion research planning. PeptideStack separates research-use-only peptide information from FDA-approved medication and licensed telehealth pathways. Research peptide pages are informational and are not medical advice, prescription guidance, dosing instructions, treatment recommendations, or instructions for human consumption. Many pages include affiliate disclosures because PeptideStack may earn a commission when visitors click external supplier or telehealth links. That commission does not change the price paid by visitors and does not mean PeptideStack manufactures, sells, distributes, compounds, or ships peptides or medications. Supplier and product pages should be evaluated for third-party testing, batch-specific certificates of analysis, named laboratory verification, transparent pricing, realistic delivery expectations, payment security, refund policies, support quality, and consistent research-use-only labeling. Blog pages connect related guides, comparison articles, FDA approval status explainers, safety context, legality resources, product pages, vendor reviews, and calculator tools so visitors can keep researching without relying on a single supplier claim. Calculator pages are educational tools for laboratory planning and should be cross-checked against professional protocols, institutional requirements, and applicable laws. Legal and disclaimer pages explain the boundaries of PeptideStack content and the responsibility of visitors who evaluate third-party vendors. The rendered interface may add interactive details such as mobile navigation labels, product tabs, share buttons, related article cards, disclosure boxes, call-to-action buttons, vendor selectors, copy-code controls, email-code forms, footer navigation, and status labels. The static HTML fallback includes this context so the same page purpose is understandable before the JavaScript application finishes loading. Visitors should treat PeptideStack as a research and comparison starting point. Final supplier evaluation should include direct review of the external vendor website, current product availability, checkout terms, applicable laws, institutional requirements, and any third-party laboratory documentation available for the exact product or batch being considered. Footer resources repeat important sitewide context: PeptideStack is independent, affiliate-supported, research-focused, and not a pharmacy or manufacturer. Pages may include links to the iOS app, calculators, blog hubs, product hubs, supplier comparisons, support contact, and policy documents. This repeated context is intentionally available in the raw HTML for crawlers that inspect a page before executing the React bundle. Raw HTML also includes page summaries for mobile crawlers using JavaScript rendering, desktop crawlers comparing source to rendered output, accessibility tools, and no-script visitors. The fallback is replaced by the React app in normal browsers but keeps the source document aligned with the visible page topic. This fallback keeps source HTML and rendered HTML closer for crawl diagnostics and SEO audits across crawled pages, routes, reports, and recrawls.